Sangamo Therapeutics, Inc. received FDA Fast Track Designation for ST-503, an investigational epigenetic regulator for treating intractable pain due to small fiber neuropathy (SFN). This designation aims to expedite the development and review of new therapeutics for serious conditions like SFN. The Phase 1/2 STAND study is currently underway to evaluate ST-503, with recruitment ongoing. SFN affects 53 out of 100,000 people in the U.S. and lacks effective treatment options. Sangamo’s goal is to develop safe, nonopioid alternatives for SFN patients, with the first patient in the study expected to be dosed soon.

Read more at GlobeNewswire: Sangamo Therapeutics Receives U.S. FDA Fast Track